Humana (HUM) was downgraded to underperform by BofA, which cited an ongoing delay in margin recovery amid news the company ...
Analyst Erin Wright of Morgan Stanley maintained a Hold rating on Humana (HUM – Research Report), with a price target of $374.00. Erin ...
Medicare Advantage quality ratings for the company dropped, meaning a big drop in revenue from bonus payments.
The recent developments have cratered Humana stock price, and it is now trading under our earlier targets. Read why we remain ...
Humana (HUM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Baxter from ...